Medicare AdvantagePrior AuthMedium impact
Brekiya® (dihydroergotamine mesylate) (Revised)
Humana·Neurology, Pain Management, Family Medicine +1 more·Medicare Advantage
We identified it
Jul 21, 2026
Summary
This is a revised Prior Authorization policy for Brekiya® (dihydroergotamine mesylate) affecting Medicare Advantage members. The policy update requires billing teams to verify current prior authorization requirements and any changes to coverage criteria, medical necessity documentation, or approval procedures for this migraine treatment medication.
Action Required
Immediately: Billing and clinical staff must obtain and review the full policy document from the source URL (https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a5847ee) to identify specific prior authorization requirements, approved diagnoses, dosing limits, or documentation requirements for Brekiya®. Update internal prior authorization workflow and provider communication materials to reflect any changes from the previous version. Verify with Humana if an effective date applies and communicate revised requirements to prescribing providers. Claims submitted without proper prior authorization per the updated policy will be denied.